Actively Recruiting
Comparison of CPAP Treatment Alone Versus CPAP Combined with a Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients with Resistant Hypertension
Led by AGIR à Dom · Updated on 2025-02-20
100
Participants Needed
5
Research Sites
N/A
Total Duration
On this page
Sponsors
A
AGIR à Dom
Lead Sponsor
U
University Hospital, Grenoble
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the combined effect of CPAP treatment and a physical activity program on 24-hour blood pressure control in patients with obstructive sleep apnea syndrome (OSAS) and resistant hypertension. OSAS is closely linked to higher cardiovascular risk and is a leading cause of resistant hypertension, affecting up to 80% of such patients. Previous studies showed CPAP alone improves blood pressure modestly, but combining treatments may offer better control. The study compares two groups: one receiving standard CPAP treatment plus a physical activity program, and the other receiving CPAP treatment alone. The physical activity program involves sessions three times per week for 12 weeks. CPAP is used to suppress OSAS, and the trial aims to assess whether adding exercise improves blood pressure outcomes more effectively than CPAP alone. Participants will undergo 24-hour home blood pressure monitoring at the start and after 12 weeks to measure systolic, diastolic, and mean arterial pressure. Researchers will also track physical activity levels, pulse wave velocity, and sleep duration. The study includes regular assessments over 12 weeks, monitoring changes in blood pressure and activity to evaluate the combined treatment's impact. The total participation period covers the 12-week intervention and follow-up assessments.
CONDITIONS
Brief Title
Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with obstructive sleep apnea (apnea-hypopnea index ≥ 15)
- Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents
- Ambulatory patient
- Age between 18 and 80 years
You will not qualify if you...
- Acute hepatic failure, biliary cirrhosis, or cholestasis
- Acute hypertension with systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg
- Contraindication to CPAP treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants undergo CPAP treatment and those in the experimental arm participate in a physical activity program three times per week for 12 weeks to help reduce blood pressure.
Three visits per week for physical activity sessions
Trial Site Locations
Total: 5 locations
1
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
Québec, Canada
Actively Recruiting
2
Hopital Universitaire de Grenoble
La Tronche, France, 38700
Actively Recruiting
3
Clinique Pasteur
Toulouse, France, 31300
Actively Recruiting
4
Hopitaux Universitaires de Genève
Geneva, Switzerland
Withdrawn
5
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Withdrawn
Research Team
J
Jean-Louis Pépin, Pr MD PhD
S
Sandrine Bouzon
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here